The IRS defended its denial of AbbVie’s claimed deduction for a $1.6 billion payment to a biotechnology company over their failed merger, telling the U.S. Tax Court that the pharmaceutical giant is misconstruing an underlying statute to challenge the agency’s decision.
AbbVie Can’t Get Deduction For $1.6B Merger Fee, IRS Says
by usoftax_admin | Apr 18, 2024 | Tax News